Elanco Announces Launch of Zenrelia™ for Canine Dermatology
Elanco Animal Health Incorporated (NYSE: ELAN) is making a significant stride in pet health with the introduction of Zenrelia™ (ilunocitinib), an innovative treatment for itchy dogs. The approval from the European Commission brings forth a promising option for controlling itching due to allergic dermatitis and atopic dermatitis in dogs aged twelve months and older.
Significant Milestone in Pet Health Innovation
This remarkable product is a once-daily oral JAK inhibitor designed to deliver effective relief. With Zenrelia's arrival in the EU market, Elanco aims to revolutionize the standard of care, enabling pet owners and veterinarians to manage pruritus more conveniently than ever.
Dr. Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs at Elanco, highlighted, "Our EU approval is a pivotal achievement, reinforcing our leadership in pet health innovation. We’re thrilled to provide such an impactful solution to alleviate suffering among countless dogs with itchy skin. Our studies have shown positive results compared to existing treatments, particularly in real-world scenarios where Zenrelia is already in use. This product has already shown promise in other global markets, enhancing our confidence in its efficacy and safety."
Product Availability and Market Expansion
Zenrelia is set to launch immediately with availability anticipated before the third quarter ends, marking a significant development in the European canine dermatology landscape. Elanco is also optimistic about extending Zenrelia's reach in other key markets where it has already received approval, including regions beyond North America.
Ramiro Cabral, Executive Vice President of Elanco International, shared the company’s excitement regarding this new launch. “We're eager to provide veterinarians and pet owners a reliable solution for their pets’ dermatological issues with Zenrelia, which brings the convenience of a single daily dose.” He further noted that this expansion complements Elanco's growing portfolio of pet health solutions in Europe, which includes notable products such as AdTab, Credelio, and Galliprant.
Research Backing Zenrelia's Approval
As part of Zenrelia’s approval process, Elanco conducted rigorous research through a non-inferiority study against the well-established product Apoquel. The study involved 338 client-owned dogs confirmed to have atopic dermatitis, conducted across multiple sites in various countries. Results demonstrated that a single daily dose of Zenrelia is at least as effective as the competitor, showing promising outcomes within 28 days. The comprehensive findings of this study were published in a prestigious peer-reviewed journal.
More information regarding the marketing authorization and product details will soon be made available on the European Commission website.
About Elanco Animal Health
Elanco Animal Health, a global leader in the industry, has a rich history of over 70 years in innovating products destined to enhance the health of animals. With a vision of promoting companionship and food security, Elanco commits to delivering effective solutions to farmers, pet owners, and veterinarians. This commitment is encapsulated in their Healthy Purpose™ sustainability pillars aimed at bettering both animal and human health, while also considering the well-being of our planet.
Frequently Asked Questions
What is Zenrelia™ and its intended use?
Zenrelia™ (ilunocitinib) is a once-daily oral medication designed to treat pruritus associated with allergic and atopic dermatitis in dogs aged 12 months and older.
How does Zenrelia™ compare to existing treatments?
Zenrelia™ has shown non-inferiority compared to the leading product Apoquel, proving to be as effective in alleviating itching in dogs throughout clinical trials.
What countries has Zenrelia been approved in?
Besides the European Union, Zenrelia is available in multiple regions including Brazil, Canada, Japan, and the United States, with further approvals anticipated.
When will Zenrelia™ be available in the European market?
The product is set to become available shortly, with expectations for availability in the market by the end of the third quarter of the upcoming year.
What does Elanco's vision encapsulate?
Elanco's vision includes enhancing the health of animals, creating value for stakeholders, and ensuring a sustainable future that encompasses improved health for animals, people, and the planet.
